Billing Code Overview

HCPCS Level II code S0191 represents Misoprostol, oral, 200 mcg supplied for clinical use. This is classified as a drug administration / supply code (HCPCS Level II, Non‑Medicare Drug Code). The typical site of service for claims using this code is an office setting (POS 11).

Data not available in the input.

Clinical Context

A reproductive-age patient presents to the office seeking medical management for heavy menstrual bleeding or contraceptive care. The clinician discusses options and prescribes oral misoprostol, 200 mcg, for indicated use such as medical management of early pregnancy loss or adjunctive therapy as clinically appropriate. The medication is dispensed or administered in the office (Place of Service 11). The visit typically includes assessment, counseling, and documentation of informed consent, followed by supply or administration of the HCPCS Level II code S0191. Billing occurs for the drug supply using HCPCS Level II code S0191, and a separate evaluation and management visit may be billed if a significant, separately identifiable service is performed on the same day.

Coding Specifications

• Modifier 25: Use when a significant, separately identifiable evaluation and management (E/M) service is provided by the same physician on the same day as the HCPCS Level II code S0191. Apply when documentation supports an E/M beyond usual pre-administration counseling.

• Modifier 59: Use to indicate a distinct procedural service when S0191 is billed on the same day as another procedure or service that would otherwise be bundled; apply only when clinical documentation supports that the services are separate and distinct.

• Associated Provider Taxonomies:

These taxonomies represent clinicians who commonly prescribe or supply the drug represented by HCPCS Level II code S0191 in office settings.

Related Diagnoses

• Z30.013 — Encounter for initial prescription of injectable contraceptive

  Relevance: May be used when the visit includes initiation of contraceptive management and the clinician documents contraceptive counseling alongside supply of HCPCS Level II code S0191.

• Z30.42 — Encounter for surveillance of injectable contraceptive

  Relevance: Applies to follow-up surveillance visits for injectable contraceptives; may be documented when contraceptive management is reviewed and S0191 is supplied during the visit.

• Z30.49 — Encounter for surveillance of other contraceptives

  Relevance: Applicable when monitoring use of non-injectable contraceptives; relevant if S0191 is provided as part of contraceptive care.

• Z30.9 — Encounter for contraceptive management, unspecified

  Relevance: Use when the visit pertains to contraceptive management without a more specific code; may coexist with documentation supporting billing for HCPCS Level II code S0191.

• N92.0 — Excessive and frequent menstruation with regular cycle

  Relevance: Relevant when S0191 is supplied as part of medical management for abnormal uterine bleeding or symptomatic control associated with heavy menstrual bleeding.

Related Codes

96372 may be billed when a separate injectable medication administration is performed during the same visit and is clinically distinct from dispensing S0191.

99213 and 99214 represent common E/M visit levels that may accompany billing for HCPCS Level II code S0191 when evaluation and management services are provided; use Modifier 25 when an E/M is separately identifiable on the same day.

J1050 is a drug-specific HCPCS Level II code for injectable medroxyprogesterone acetate and may be used as an alternative drug supply code in workflows where that medication is supplied instead of the oral misoprostol represented by HCPCS Level II code S0191.

National mean rates for HCPCS Level II code S0191 show sizable divergence between Medicare and average commercial benchmarks: Medicare’s mean rate is $1.00 while BUCA (average commercial) has a mean of $1.88, indicating commercial payers on average reimburse higher than Medicare for this code. Aetna’s national mean rate of $6.29 is an outlier well above both Medicare and BUCA.

Rate dispersion (P75 minus P25) is tight (zero dispersion) for Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA (average commercial), and Medicare, where the 25th, 50th, and 75th percentiles are all $1.00. Aetna shows wider dispersion with a P25 of $0.20 and P75 of $1.00, a difference of $0.80. The table and chart below present the full breakdown.